Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia

Australasian Journal of Dermatology

Volumn 54, Issue 1, 2013, Pages 49-51

  Boyapati, Ann ^a   Sinclair, Rodney ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

androgenetic alopecia; dutasteride; finasteride; male pattern hair loss

Indexed keywords

DUTASTERIDE; FINASTERIDE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; HAIR GROWTH; HUMAN; LOW DRUG DOSE; MALE; MALE TYPE ALOPECIA; TREATMENT RESPONSE;

5-ALPHA REDUCTASE INHIBITORS; ALOPECIA; AZASTEROIDS; DRUG THERAPY, COMBINATION; FINASTERIDE; HUMANS; MALE; MIDDLE AGED;

EID: 84873408493     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2012.00909.x     Document Type: Article

References (13)

1. Sinclair R,. Male pattern androgenetic alopecia. Br. Med. J. 1998; 317: 865-9.
2. Kaufman KD, Olsen EA, Whiting D, et al,. Finasteride in the treatment of men with androgenetic alopecia. J. Am. Acad. Dermatol. 1998; 39: 578-88.
3. Leyden J, Dunlap F, Miller B, et al,. Finasteride in the treatment of men with frontal male pattern hair loss. J. Am. Acad. Dermatol. 1999; 40: 930-7.
4. The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur. J. Dermatol. 2002; 12: 38-49.
5. Olsen EA, Hordinsky M, Whiting D, et al,. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J. Am. Acad. Dermatol. 2006; 55: 1014-23.
6. Azzouni F, Godoy A, Li Y, et al,. The 5 α-reductase isozyme family: a review of basic biology and their role in human diseases. Adv. Urol. 2012; doi 10.1155/2012/530121 [Epub ahead of print].
7. Bayne EK, Flanagan J, Einstein M, et al,. Immunohistochemical localization of types 1 and 2 5α-reductase in human scalp. Br. J. Dermatol. 1999; 141: 481-91.
8. Godoy A, Kawinski E, Li Y, et al,. 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 2011; 71: 1033-46.
9. Clark RV, Hermann DJ, Cunningham GR, et al,. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 α-reductase inhibitor. J. Clin. Endocrinol. Metab. 2004; 89: 2179-84.
10. Drake L, Hordinsky M, Fiedler V, et al,. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J. Am. Acad. Dermatol. 1999; 41: 550-4.
11. GlaxoSmithKline. Avodart (dutasteride) soft gelatin capsules prescribing information. October 2011. Available from URL: http://us.gsk.com/products/ assets/us-avodart.pdf. (Accessed 23 Mar 2012.)
12. Debruyne F, Barkin J, van Erps P, et al,. Efficacy and safety of long-term treatment with the dual 5-α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur. Urol. 2004; 46: 488-95.
13. Uemura M, Tamura K, Chung S, et al,. Novel 5 α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008; 99: 81-6.